NCT06440954View on ClinicalTrials.gov

Efficacy and Resistance Mechanisms of IP in NSCLC With Leptomeningeal Metastases

PHASE2RecruitingINTERVENTIONAL
Enrollment

220

Participants

Timeline

Start Date

May 1, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

April 30, 2027

Conditions
Non-Small Cell Lung Cancer
Interventions
DRUG

Intrathecal pemetrexed

Intrathecal pemetrexed(50mg) twice a week for 1 week (day 1 and day 5) as induction treatment, then once monthly until progressive disease.

Trial Locations (1)

410013

RECRUITING

Hunan Cancer Hospital, Changsha

All Listed Sponsors
collaborator

Hunan Cancer Hospital

OTHER

lead

Hunan Province Tumor Hospital

OTHER